Complete and long‑term response of HER2 positive locally highly advanced metastatic breast cancer – case report


MUDr. Lenka Rušinová; doc. MUDr. Renata Soumarová, Ph.D.; MUDr. Marián Liberko

Radioterapeutická a onkologická klinika 3. LF UK a FN Královské Vinohrady, Praha



Unfortunately, we are currently encountering locally very advanced and generalized breast cancers. However, due to systemic therapy and especially targeted therapy, we can see excellent long-term responses in patients with HER2 positive tumors. The discovery of novel products targeting the extracellular domain of the human epidermal growth factor receptor 2 (HER2) and the combination of this monoclonal antibody with the microtubule inhibitor T-DM1 (trastuzumab emtansine) has resulted in a statistically significant increase in overall survival and has changed metastatic HER2 positive breast cancer to chronic disease.


Key words

breast cancer, locally advanced cancer, HER2 positive cancer, targeted treatment



The full article is only available to subscribers

Become a regular subscriber to our Oncological Review...